IRCT201010094269N3.

Methods	This is a double‐blinded randomised clinical trial
Participants	Inclusion criteria of the trial Gender: both Participants with mild to moderate acne in age range 11 to 30 years old Participants who have maximum 20 inflammatory lesions (papules and pustules) on one side of the face and have not more than three nodules or cysts on the same side of the face Lack of other face dermatosis such as contact dermatitis, allergic or seborrhoeic dermatitis Patient satisfaction Exclusion criteria of the trial Participants using topical or systemic steroids Participants using contraceptive pills (anti‐androgen) Participants who used topical or oral anti‐acne medications, during the previous month, including natural and UV light and herbal and traditional acne treatments Other face dermatosis and systemic acne accelerator diseases, such as Cushing's syndrome, polycystic ovary syndrome, adrenal hyperplasia, acquired and innate immune deficiency, steroid acne and acneiform lesions Participants with more than 20 inflammatory lesions (papules and pustules) and three nodules or cysts on one side of the face Participants with acne excoriee Age under 11 y/o and over 30 y/o Participants with an inflammatory disease, except acne, on the face such as contact dermatitis, allergic or seborrhoeic dermatitis
Interventions	Intervention group: combination of erythromycin 4 g and salicylic acid in 10 cc propylene glycol and alcohol 70 degrees to an overall volume of 100 cc applied to the face with cotton applicator twice a day for 3 months. Control group: combination of erythromycin 4 g in 10 cc propylene glycol and alcohol 70 degrees to an overall volume of 100 cc applied to the face with cotton applicator twice a day for 3 months. Total number of participants enrolled: 50
Outcomes	Primary outcome of the trial Acne severity index. Timepoint: every 15 days. Method of measurement: history, physical examination, counting and statistical evaluation Secondary outcomes of the trial Comedon. Timepoint: every 15 days. Method of measurement: physical examination and counting Papule. Timepoint: every 15 days. Method of measurement: physical examination and counting Patient satisfaction. Timepoint: every 15 days. Method of measurement: history Pustule. Timepoint: every 15 days. Method of measurement: physical examination and counting Side effect of treatment. Timepoint: every 15 days. Method of measurement: history and physical examination Total numbers of lesions. Timepoint: every 15 days. Method of measurement: physical examination and counting
Notes	Study completed, no results. The email we sent to the study authors had been rejected for unknown reason.